In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Viking Therapeutics Inc (NASDAQ: VKTX) closed the day trading at $34.86 up 2.74% from the previous closing price of $33.93. In other words, the price has increased by $2.74 from its previous closing price. On the day, 3.96 million shares were traded. VKTX stock price reached its highest trading level at $35.1 during the session, while it also had its lowest trading level at $33.425.
Ratios:
For a better understanding of VKTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 36.47 and its Current Ratio is at 36.47. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 22, 2024, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $109.
H.C. Wainwright reiterated its Buy rating for the stock on November 04, 2024, while the target price for the stock was revised from $90 to $102.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 06 ’25 when Lian Brian sold 194,490 shares for $42.75 per share. The transaction valued at 8,313,601 led to the insider holds 2,366,570 shares of the business.
Mancini Marianna sold 54,215 shares of VKTX for $2,317,599 on Jan 06 ’25. The Chief Operating Officer now owns 374,134 shares after completing the transaction at $42.75 per share. On Jan 06 ’25, another insider, ZANTE GREG, who serves as the Chief Financial Officer of the company, sold 50,309 shares for $42.75 each. As a result, the insider received 2,150,595 and left with 165,259 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VKTX now has a Market Capitalization of 3884658944 and an Enterprise Value of 2955467264.
Stock Price History:
The Beta on a monthly basis for VKTX is 0.94, which has changed by 0.6203438 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, VKTX has reached a high of $99.41, while it has fallen to a 52-week low of $20.28. The 50-Day Moving Average of the stock is -29.46%, while the 200-Day Moving Average is calculated to be -41.36%.
Shares Statistics:
Over the past 3-months, VKTX traded about 4.44M shares per day on average, while over the past 10 days, VKTX traded about 2998150 shares per day. A total of 111.43M shares are outstanding, with a floating share count of 107.97M. Insiders hold about 3.11% of the company’s shares, while institutions hold 73.77% stake in the company. Shares short for VKTX as of 1735603200 were 19468391 with a Short Ratio of 4.38, compared to 1732838400 on 18071399. Therefore, it implies a Short% of Shares Outstanding of 19468391 and a Short% of Float of 23.47.
Earnings Estimates
Currently, 12.0 analysts are dedicated to thoroughly evaluating and rating the performance of Viking Therapeutics Inc (VKTX) in the stock market.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.24 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.91 and -$1.09 for the fiscal current year, implying an average EPS of -$0.96. EPS for the following year is -$1.42, with 11.0 analysts recommending between -$1.06 and -$2.04.
